D2HGDH 缺乏通过GSH/Prdx6/ROS介导的激发性突触活动来调节发作
Zhijuan Zhang1, Hui Zhang1, Peng Zhang2
1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Neurology, Chongqing, 400016, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 31, 2024
概括
降低D-2-基酸脱酶 (D2HGDH) 的调节会通过增加氧化应激增加的风险. 通过像MJ33这样的疗法准D2HGDH可能为耐药性提供新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 遗传学 是一个
背景情况:
- 影响了三分之一的患者对当前治疗无反应.
- 精准医学需要识别与有关的基因.
- 氧化应激和突触功能障碍与病原发生有关.
研究的目的:
- 研究D-2-基酸脱酶 (D2HGDH) 在中的作用.
- 通过突触功能探索D2HGDH在网络中的参与.
- 确定是否针对D2HGDH提供了耐火性的治疗策略.
主要方法:
- 在神经元中下调D2HGDH表达.
- 测量了减少的谷氨 (GSH) /氧化谷氨 (GSSG) 的比例和活性氧物种 (ROS) 水平.
- 使用一种酸独立的酸酶A2 (aiPLA2) 抑制剂,MJ33.3.
主要成果:
- 降低D2HGDH降低了GSH/GSSG比率,并增加了神经元中的ROS水平.
- 降低D2HGDH的调节与突触传输的改变和增加发作易感性有关.
- MJ33治疗恢复了GSH/GSSG平衡,减少了ROS,并改善了与有关的行为.
结论:
- D2HGDH下调影响通过调节ROS产生的突触功能.
- 向D2HGDH可能是耐火性的可行治疗方法.
- 基因疗法或向D2HGDH通路的抗氧化剂策略在治疗中表现有前途.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
325
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
325
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
442
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
442
Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K


